Haier Biomedical's European Summit in Rome Sets Stage for Future Growth and Innovation
Haier Biomedical recently hosted its European Partner Summit in the heart of Rome, gathering 37 partners and industry leaders from 23 European countries. The summit, themed "Advancing Together - Sharing the Future of Biomedical Innovation," aimed to strengthen the company's long-term investment in Europe while unveiling an upgraded laboratory solutions portfolio.
In a keynote presentation, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the company’s commitment to achieving over 50% of its global revenue from international markets by 2027. He highlighted that Europe plays a crucial role in this strategy, underlining the "In Europe, for Europe" principle. This approach focuses on tailoring products and services to align with regional regulatory standards, customer expectations, and market needs.
The 2026 European strategy was further elaborated by Semir Selimovic, Director of North, Central, and Eastern Europe at Haier Biomedical. He stressed the significance of ongoing investments in local sales and service capabilities to enhance operational responsiveness across key markets. Europe has been identified as one of the fastest-growing regions for the company, which is supported by a robust expansion of local teams and an increasingly diverse product range.
Among the exciting new offerings introduced at the summit, the Plasma Apheresis System XJ-III shined as a notable addition. This new system has already achieved EU MDR certification, marking a significant milestone in meeting Europe's rigorous regulatory standards while bolstering Haier Biomedical’s presence in blood and plasma technology. Alongside it, products like CO₂ incubators, biosafety cabinets, and cold storage units continued to gain traction across Europe, reflecting the company’s commitment to efficiency and compliance.
In another pivotal aspect of the summit, Daniele Pericolini, the European Automation Solution Specialist of Haier Biomedical, outlined the ambitions to drive future growth via laboratory automation and intelligent blood management systems. The company introduced innovative biobank solutions that integrate RFID-enabled ultra-low temperature storage with modular automation platforms, aiming to enhance operational efficiency and sample traceability within laboratories.
The U-Blood intelligent blood management system was another highlight. This solution shifts the focus from traditional cold storage methods to require real-time management of blood supply chains, thereby aligning with Europe's push towards safety, digitization, and sustainable healthcare practices.
The summit also featured stories of success from four partners across Europe, showcasing local validation and exceeding customer expectations. A partner in France displayed their customized biosafety cabinet that met French regulations, illustrating successful deployment across multiple clients. Meanwhile, in Denmark, another partner highlighted their achievements with ultra-low temperature freezers, adding credibility to Haier Biomedical's expanding portfolio.
Performance metrics further underscore the success and growth trajectory of Haier Biomedical. In 2025, the company recorded a revenue exceeding RMB 2.3 billion, with international earnings constituting over 36% of the total revenue. European operations notably drove double-digit growth, contributing significantly to international revenue expansion. Their automation and AI solutions impacted around 15% of this revenue.
As the European Partner Summit concluded, Haier Biomedical reinforced its commitment to strengthening localized operations in Europe while advancing collaborative growth with its partners. The company’s combination of global innovation capabilities and localized execution aims to solidify its position as a trusted provider of life science solutions moving into the future. With this strategic direction, stakeholders eagerly anticipate further developments from Haier Biomedical in the coming years.
For more information, please visit Haier Biomedical.
In a keynote presentation, Enrique Wang, Global Market Director of Haier Biomedical, reaffirmed the company’s commitment to achieving over 50% of its global revenue from international markets by 2027. He highlighted that Europe plays a crucial role in this strategy, underlining the "In Europe, for Europe" principle. This approach focuses on tailoring products and services to align with regional regulatory standards, customer expectations, and market needs.
The 2026 European strategy was further elaborated by Semir Selimovic, Director of North, Central, and Eastern Europe at Haier Biomedical. He stressed the significance of ongoing investments in local sales and service capabilities to enhance operational responsiveness across key markets. Europe has been identified as one of the fastest-growing regions for the company, which is supported by a robust expansion of local teams and an increasingly diverse product range.
Among the exciting new offerings introduced at the summit, the Plasma Apheresis System XJ-III shined as a notable addition. This new system has already achieved EU MDR certification, marking a significant milestone in meeting Europe's rigorous regulatory standards while bolstering Haier Biomedical’s presence in blood and plasma technology. Alongside it, products like CO₂ incubators, biosafety cabinets, and cold storage units continued to gain traction across Europe, reflecting the company’s commitment to efficiency and compliance.
In another pivotal aspect of the summit, Daniele Pericolini, the European Automation Solution Specialist of Haier Biomedical, outlined the ambitions to drive future growth via laboratory automation and intelligent blood management systems. The company introduced innovative biobank solutions that integrate RFID-enabled ultra-low temperature storage with modular automation platforms, aiming to enhance operational efficiency and sample traceability within laboratories.
The U-Blood intelligent blood management system was another highlight. This solution shifts the focus from traditional cold storage methods to require real-time management of blood supply chains, thereby aligning with Europe's push towards safety, digitization, and sustainable healthcare practices.
The summit also featured stories of success from four partners across Europe, showcasing local validation and exceeding customer expectations. A partner in France displayed their customized biosafety cabinet that met French regulations, illustrating successful deployment across multiple clients. Meanwhile, in Denmark, another partner highlighted their achievements with ultra-low temperature freezers, adding credibility to Haier Biomedical's expanding portfolio.
Performance metrics further underscore the success and growth trajectory of Haier Biomedical. In 2025, the company recorded a revenue exceeding RMB 2.3 billion, with international earnings constituting over 36% of the total revenue. European operations notably drove double-digit growth, contributing significantly to international revenue expansion. Their automation and AI solutions impacted around 15% of this revenue.
As the European Partner Summit concluded, Haier Biomedical reinforced its commitment to strengthening localized operations in Europe while advancing collaborative growth with its partners. The company’s combination of global innovation capabilities and localized execution aims to solidify its position as a trusted provider of life science solutions moving into the future. With this strategic direction, stakeholders eagerly anticipate further developments from Haier Biomedical in the coming years.
For more information, please visit Haier Biomedical.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.